Could Investors Overdose on Pharmaceuticals?

Michael McTague | |


Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies

Edward Kim | |

The company is in Phase 3 trials with atrasentan for IgA nephropathy (IgAN).

BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million

Edward Kim | |

BMY will pay BBIO $90 million in upfront cash.

PepGen Goes Public in $108 Million IPO

Edward Kim | |

The company is developing treatments for serious genetic diseases, with an initial focus on neuromuscular diseases.

Aeglea BioTherapeutics Raises $45 Million Via Registered Direct Offering

Edward Kim | |

The company is waiting on FDA review of its lead product candidate.

Biogen CEO Michel Vounatsos To Step Down After Commercial Failure of Alzheimer's Drug

Edward Kim | |

Biogen will also halt marketing of Aduhelm.

Five Fallen Biotech Stocks We're Watching for Rebounds

Edward Kim | |

We think opportunities abound in the sector.

Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins

Edward Kim | |

The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.

Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger

Edward Kim | |

The company will merge with Isleworth Healthcare Acquisition Corp.

WHO Endorses Pfizer's Oral COVID-19 Treatment Paxlovid for High-Risk Patients

Equities Staff | |

Paxlovid may be the most potent COVID-19 therapy currently available.

Sponsored Financial Content

Market Movers